The number of major employers offering employee wellness programs with incentives grew over the past year, according to a study presented by Health2 Resources. The National Association of Manufacturers and The ERISA Industry Committee participated in the survey.
The number of major employers offering employee wellness programs with incentives grew over the past year, according to a study presented by Health2 Resources. The National Association of Manufacturers and The ERISA Industry Committee participated in the survey.
Results show that between 2007 and 2008, there was an increase in the proportion of employers offering incentives for health and wellness, from 62% of companies with programs to 71% in 2008. That’s a 15% overall jump in one year. Incentives vary from offering cash for weight loss to gifts cards for filing out a health risk questionnaire.
In 2007, the top choice among incentives was premium reductions (41%), followed by gift cards (17%). This year, however, gift cards are the top choice (28%), closely followed by premium reductions (26%) and cash (24%). Use of cash bonuses and health savings account contributions remained roughly the same.
The value of an incentive is typically between $100 and $300 per-employer, per-year. Incentives range from a low of $5 to a high of $600 per-person, per-year, and are most commonly leveraged to encourage participation.
Respondents reported giving out incentives for health-program participation 48% of the time, for program completion 38% of the time, and for achieving specific health-related goals or outcomes during the program 16% of the time.
More employers are measuring their returns for the programs as well. Some 83% of those who measure say they are achieving better than a 1-to-1 return.
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen